Shamburg News · 8-K filed Nov 10, 2026, 4:28 PM EST
Inhibikase Therapeutics Reports Third Quarter 2026 Results With $20.5 Million Net Loss
IKT · Inhibikase Therapeutics, Inc.
- Earnings
- Materiality: high
Inhibikase Therapeutics reported a net loss of $20.5 million, or $0.10 per share, for the quarter ended September 30, 2026, compared with a net loss of $11.9 million, or $0.13 per share, for the same quarter of 2025. Research and development expenses were $15.0 million for the quarter, and cash, cash equivalents and marketable securities were $193.3 million as of September 30, 2026. The press release also reported 28 country regulatory approvals and 79 activated clinical sites for the Phase 3 IMPROVE-PAH study, and a July 2026 sale of 25,000,000 shares to RA Capital for $50 million in gross proceeds.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-455560.
Written from the filing by Shamburg Markets. Figures are as reported by the company.